Comprehensive manipulation of glycosylation profiles across development scales. Issue 2 (17th February 2019)

• Record Type: Journal Article
• Authors: Loebrich, Sven; Clark, Elisa; Ladd, Kristina; Takahashi, Stefani; Brousseau, Anna; Kitchener, Seth; Herbst, Robert; Ryll, Thomas
• Is Part Of: MAbs. Volume 11:Issue 2(2019)
• Page Start: 335
• Page End: 349
• Publication Date: 2019-02-17
• Subjects: glycosylation -- product quality -- ADC -- media development -- feed additives -- DoE -- multivariate analysis -- scalability; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2018.1527665
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: The extent and pattern of glycosylation on therapeutic antibodies can influence their circulatory half-life, engagement of effector functions, and immunogenicity, with direct consequences to efficacy and patient safety. Hence, controlling glycosylation patterns is central to any drug development program, yet poses a formidable challenge to the bio-manufacturing industry. Process changes, which can affect glycosylation patterns, range from manufacturing at different scales or sites, to switching production process mode, all the way to using alternative host cell lines. In the emerging space of biosimilars development, often times all of these aspects apply. Gaining a deep understanding of the direction and extent to which glycosylation quality attributes can be modulated is key for efficient fine-tuning of glycan profiles in a stage appropriate manner, but establishment of such platform knowledge is time consuming and resource intensive. Here we report an inexpensive and highly adaptable screening system for comprehensive modulation of glycans on antibodies expressed in CHO cells. We characterize 10 media additives in univariable studies and in combination, using a design of experiments approach to map the design space for tuning glycosylation profile attributes. We introduce a robust workflow that does not require automation, yet enables rapid process optimization. We demonstrate scalability across deep wells, shake flasks, AMBR-15 cell culture system, and 2 L single-use bioreactors. Further, we show that it is broadly applicable to different molecules and host cell lineages. This universal approach permits fine-tuned modulation of glycan product quality, reduces development costs, and enables agile implementation of process changes throughout the product lifecycle.